You are viewing the site in preview mode

Skip to main content


  • Poster presentation
  • Open Access

Targeting of phosphatidylserine by monoclonal antibodies enhances activity of immune checkpoint inhibitors in breast tumors

  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 2 and
  • 1
Journal for ImmunoTherapy of Cancer20142 (Suppl 3) :P206

  • Published:


  • Breast Cancer
  • Breast Tumor
  • Phosphatidylserine
  • Inhibit Tumor Growth
  • Immune Checkpoint

Phosphatidylserine (PS) is a phospholipid normally residing in the inner leaflet of the plasma membrane and becomes exposed on tumor vascular endothelial cells (ECs) and tumor cells. PS exposure becomes enhanced in response to chemotherapy, irradiation, and oxidative stresses in the tumor microenvironment. PS exposure in tumors promotes an immunosuppressive microenvironment which includes the recruitment of myeloid derived suppressor cells (MDSCs), immature dendritic cells, and M2-like macrophages as well as the production of anti-inflammatory cytokines [1]. In the present study, we evaluated the effect of a PS-targeting and anti-PD-1 antibodies in EMT-6 breast tumor model in Balb/c mice. Combination therapy inhibited tumor growth greater than the single agent therapies. Tumor growth inhibition correlates with infiltration of immune cells in tumors and induction of adaptive immunity. The combination of these mechanisms promotes strong, localized, anti-tumor responses without the side-effects of systemic immune activation. Our data demonstrate that combination of antibodies that block PS in combination with antibodies that block PD-1 may be promising therapy for breast cancer.

Authors’ Affiliations

Peregrine Pharmaceuticals, Inc, Tustin, CA, USA
Department of Clinical Affairs, Peregrine Pharmaceuticals Inc., Tustin, CA, USA


  1. Yin Y, Huang X, Lynn K, Thorpe P: Phosphatidylserine-targeting antibody induces M1 macrophage polarization and promotes myeloid-derived suppressor cell differentiation. Cancer Immunol Res. 1 (4): 256-68.Google Scholar


© Gong et al.; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.